167 related articles for article (PubMed ID: 36149726)
1. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S; Hiraoka A; Casadei-Gardini A; Tsutsumi T; Nakano D; Iwamoto H; Tada F; Rimini M; Tanaka M; Torimura T; Suga H; Ohama H; Burgio V; Niizeki T; Moriyama E; Suzuki H; Shirono T; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
Hepatol Res; 2023 Feb; 53(2):104-115. PubMed ID: 36149726
[TBL] [Abstract][Full Text] [Related]
2. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection.
Xiong KG; Ke KY; Chen LF; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
Hepatobiliary Pancreat Dis Int; 2023 Aug; 22(4):366-372. PubMed ID: 35466065
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
[TBL] [Abstract][Full Text] [Related]
4. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
5. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
[TBL] [Abstract][Full Text] [Related]
6. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
7. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in the Impact of Metabolic Dysfunction-associated Fatty Liver Disease on the of Patients with Hepatocellular Carcinoma After Radical Resection.
Huang J; Wei S; Tang Y; Zhang Q; Luo H; Tang Z; Tang Y; Liu H; Huang W; Dong X; Yang J
J Cancer; 2023; 14(7):1107-1116. PubMed ID: 37215444
[No Abstract] [Full Text] [Related]
12. Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients.
Lin PT; Teng W; Jeng WJ; Lin CY; Lin SM; Sheen IS
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):213-219. PubMed ID: 33177386
[TBL] [Abstract][Full Text] [Related]
13. Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease.
Yoo JJ; Park MY; Cho EJ; Yu SJ; Kim SG; Kim YJ; Kim YS; Yoon JH
J Clin Med; 2023 May; 12(9):. PubMed ID: 37176776
[TBL] [Abstract][Full Text] [Related]
14. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection.
Lin YP; Lin SH; Wang CC; Lin CC; Chen DW; Chuang CH; Huang PY; Hung CH; Yang SY; Cho WR; Chen YS; Tsai MC
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442328
[TBL] [Abstract][Full Text] [Related]
15. Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.
Batt NM; Rodrigues B; Bloom S; Sawhney R; George ES; Hodge A; Vootukuru N; McCrae C; Sood S; Roberts SK; Dev A; Bell S; Thompson A; Ryan MC; Kemp W; Gow PJ; Sood S; Nicoll AJ
J Gastroenterol Hepatol; 2024 Jun; 39(6):1048-1056. PubMed ID: 38369382
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenia Imperils Postoperative Long-Term Survival in HCC Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Propensity Score Matching Analysis.
Kong Q; Yi M; Teng F; Li H; Chen Z
J Hepatocell Carcinoma; 2023; 10():1367-1377. PubMed ID: 37605756
[TBL] [Abstract][Full Text] [Related]
17. NAFLD and MAFLD as emerging causes of HCC: A populational study.
Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
[TBL] [Abstract][Full Text] [Related]
18. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma.
Xie X; Zheng M; Guo W; Zhou Y; Xiang Z; Li Y; Yang J
Sci Rep; 2022 Aug; 12(1):13969. PubMed ID: 35978032
[TBL] [Abstract][Full Text] [Related]
19. Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis.
Sacco R; Ramai D; Tortora R; di Costanzo GG; Burlone ME; Pirisi M; Federico P; Daniele B; Silletta M; Gallo P; Cocuzza C; Russello M; Cabibbo G; Rancatore G; Cesario S; Masi G; Marzi L; Mega A; Granito A; Pieri G; Giannini EG; Paolillo R; Gadaleta-Caldarola G; Dadduzio V; Giordano G; Giacomelli L; Papa S; Renzulli M; Maida M; Ghidini M; Borzio M; Facciorusso A;
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672330
[TBL] [Abstract][Full Text] [Related]
20. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
